AZ876 is a selective, orally active agonist of liver X receptor (LXRalpha/beta) (Ki=0.007 µM [LXRalpha, human], 0.011 µM [LXRbeta, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating beta-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis[1][2].
Molekulargewicht:
439.57
Reinheit:
99.77
CAS Nummer:
[898800-26-5]
Formel:
C24H29N3O3S
Target-Kategorie:
LXR
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
